Skip to main content
. 2013 Nov 11;5(2):338–350. doi: 10.18632/oncotarget.1495

Figure 2. Pharmacokinetics of YK-4-279 in mouse models.

Figure 2

(A) Time course of (S)- YK-4-279 concentrations in male C57BL/6 mouse plasma following IV and (B) IP administration of 75 mg/kg racemic YK-4-279. (C) Six IV injections of 75 mg/kg/injection (S)-YK-4-279 for 5 Days did not show tumor regression in SCID mice (○ Control and ■ (S)-YK-4-279. (D) Plasma (S)-YK-4-279 levels correlate with xenograft tumor levels in SCID mice (R2=0.82543).